Rodman & Renshaw initiated coverage of Journey Medical with a Buy rating and $9 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Closing Bell Movers: Rumble jumps 8% on earnings
- Journey Medical reports Q2 EPS (17c), consensus (14c)
- DERM Earnings this Week: How Will it Perform?
- Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
- Journey Medical Expands Loan Facility and Strengthens Leadership